HDACi 109,
RG-2833,
RG2833,
RG2833,
1215493-56-3,
RG2833 (RGFP109),
RG-2833,
N-(6-((2-Aminophenyl)amino)-6-oxohexyl)-4-methylbenzamide,
RGFP109,
UNII-17V14R89EU,
RGFP 109,
RGFP-109,
17V14R89EU,
N-(6-(2-Aminophenylamino)-6-oxohexyl)-4-methylbenzamide,
N-[6-(2-aminophenylamino)-6-oxohexyl]-4-methylbenzamide,
VOPDXHFYDJAYNS-UHFFFAOYSA-N,
rg2833-rgfp109,
SCHEMBL529065,
GTPL7501,
CHEMBL3970532,
DTXSID20153300,
EX-A767,
BDBM207629,
HMS3653O08,
KS-00000TS9,
2684AH,
MFCD25976845,
s7292,
ZINC96170452,
AKOS030525997,
CS-1526,
AK546305,
HY-16425,
US9265734, R01,
FT-0700118,
SW219374-1,
A13139,
W-6113,
J-690067,
N-[6-(2-aminoanilino)-6-oxohexyl]-4-methylbenzamide,
N-(2-aminophenyl)-6-[(4-methylphenyl)formamido]hexanamide,
3-(1H-Indol-5-yl)-5-{4-[(4-methyl-1-piperazinyl)methyl]phenyl}-1H-pyrrolo[2,3-b]pyridine,
RG-FA,
D0GE5B,
C20H25N3O2,
A3761,
HDAC-1 inhibtors (Friedreich ataxia), RepliGen,